Skip to content

US · BCDA · BIOTECHNOLOGY

BioCardia, Inc. (BCDA) intrinsic value and stock valuation

$0.79as of 2026-11-21 · Mkt cap 10.39M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BioCardia, Inc. DCF and intrinsic value

InvestorsCraft values BCDA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BCDA’s statements →

BioCardia, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Sunnyvale, CA 94085 biocardia.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-8.23M
20112025
Free cash flow
-$-7.44M
20112025
Total equity
$900K-45.8% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$60K$480K$1.35M$1.01M
Operating income-$-8.28M-$-8M-$-11.64M-$-11.9M-$-12.63M
Net income-$-8.23M-$-7.95M-$-11.57M-$-11.91M-$-12.62M
EPSd-$-1.23M-$-2.9M-$-8.21M-$-10.09M-$-11.17M
Operating cash flow-$-7.44M-$-8.03M-$-9.97M-$-10.56M-$-10.37M
Capital expenditure-$-10K-$-10K-$-10K-$-70K-$-120K
Free cash flow-$-7.44M-$-8.03M-$-9.99M-$-10.63M-$-10.48M
Total assets$3.41M$3.72M$2.99M$9.79M$15.7M
Total debt$530K$950K$1.31M$1.63M$1.87M
Net debt-$-1.97M-$-1.42M$210K-$-5.73M-$-11M
Total equity$900K$840K-$-1.6M$4.89M$10.4M
Cash and short-term investments$2.5M$2.37M$1.1M$7.36M$12.9M
Income statement
20252024202320222021
Revenue$0.00$60K$480K$1.35M$1.01M
Cost of revenue$510K$4.39M$7.73M$8.83M$640K
Gross profit-$-510K-$-4.33M-$-7.25M-$-7.48M$380K
Research and development expenses$4.96M$4.39M$7.73M$8.83M$8.56M
Selling, general and administrative expenses$3.32M$0.00$0.00$0.00$5.09M
Other expenses-$-510K-$-720K-$-3.33M-$-4.42M-$-640K
Operating expenses$7.77M$3.67M$4.39M$4.42M$13M
Cost and expenses$8.28M$8.06M$12.1M$13.3M$13.6M
Interest income$0.00$0.00$0.00$0.00$10K
Interest expense$0.00$0.00$0.00$10K$0.00
Depreciation and amortization$510K$70K$80K$80K$60K
Ebitda-$-7.72M-$-7.88M-$-11.49M-$-11.82M-$-12.57M
Operating income-$-8.28M-$-8M-$-11.64M-$-11.9M-$-12.63M
Total other income/expenses, net$50K$50K$70K-$-10K$10K
Income before tax-$-8.23M-$-7.95M-$-11.57M-$-11.91M-$-12.62M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-8.23M-$-7.95M-$-11.57M-$-11.91M-$-12.62M
Weighted average shares outstanding$6.67M$2.74M$1.41M$1.18M$1.13M
Weighted average diluted shares outstanding$6.67M$2.74M$1.41M$1.18M$1.13M
Balance sheet
20252024202320222021
Cash and short-term investments$2.5M$2.37M$1.1M$7.36M$12.9M
Net receivables$20K$0.00$60K$200K$150K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$2.73M$2.62M$1.46M$7.86M$13.5M
Property, plant and equipment, net$510K$930K$1.36M$1.76M$2.06M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$680K$1.1M$1.53M$1.93M$2.24M
Total assets$3.41M$3.72M$2.99M$9.79M$15.7M
Accounts payable$640K$390K$890K$680K$510K
Short-term debt$440K$390K$330K$320K$240K
Deferred revenue$540K$530K$560K$960K$1.53M
Total current liabilities$2.43M$2.32M$3.61M$3.58M$3.71M
Long-term debt$90K$570K$980K$1.32M$1.63M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$90K$570K$980K$1.32M$1.63M
Capital lease obligations$530K$950K$1.31M$1.63M$1.87M
Total liabilities$2.52M$2.89M$4.59M$4.9M$5.34M
Common stock$10K$10K$0.00$20K$20K
Retained earnings-$-168.35M-$-160.12M-$-152.18M-$-140.6M-$-128.7M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$900K$840K-$-1.6M$4.89M$10.4M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$530K$950K$1.31M$1.63M$1.87M
Net debt-$-1.97M-$-1.42M$210K-$-5.73M-$-11M
Cash flow statement
20252024202320222021
Net income-$-8.23M-$-7.95M-$-11.57M-$-11.91M-$-12.62M
Depreciation and amortization$20K$70K$80K$80K$60K
Stock-based compensation$430K$740K$1.03M$1.18M$1.66M
Change in working capital-$-140K-$-1.22M$130K-$-210K-$-60K
Accounts receivable-$-20K$100K$120K-$-50K$700K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$160K-$-320K$180K$0.00-$-240K
Net cash provided by operating activities-$-7.44M-$-8.03M-$-9.97M-$-10.56M-$-10.37M
Investments in property, plant and equipment-$-10K-$-10K-$-10K-$-70K-$-120K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-10K-$-10K-$-10K-$-70K-$-120K
Common stock issued$7.76M$10.6M$4.39M$5.54M$2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$7.57M$9.3M$3.73M$5.12M$1.95M
Net change in cash$120K$1.27M-$-6.26M-$-5.51M-$-8.54M
Cash at end of period$2.5M$2.37M$1.1M$7.36M$12.9M
Operating cash flow-$-7.44M-$-8.03M-$-9.97M-$-10.56M-$-10.37M
Capital expenditure-$-10K-$-10K-$-10K-$-70K-$-120K
Free cash flow-$-7.44M-$-8.03M-$-9.99M-$-10.63M-$-10.48M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BioCardia, Inc.

        BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.

        CEO
        Peter A. Altman
        Employees
        17
        Beta
        0.49

        Explore

        Frequently asked questions

        What is the intrinsic value of BioCardia, Inc. (BCDA)?

        InvestorsCraft does not currently publish an intrinsic value for BCDA. How the IC value is calculated.

        Is BCDA undervalued?

        InvestorsCraft does not publish an undervaluation signal for BCDA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.